Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

1.

Liver fibrosis.

Bataller R, Brenner DA.

J Clin Invest. 2005 Feb;115(2):209-18. Review. Erratum in: J Clin Invest. 2005 Apr;115(4):1100.

PMID:
15690074
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Hepatic stellate cells as a target for the treatment of liver fibrosis.

Bataller R, Brenner DA.

Semin Liver Dis. 2001 Aug;21(3):437-51. Review.

PMID:
11586471
[PubMed - indexed for MEDLINE]
3.

Anti-fibrogenic strategies and the regression of fibrosis.

Kisseleva T, Brenner DA.

Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):305-17. doi: 10.1016/j.bpg.2011.02.011. Review.

PMID:
21497747
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis.

Kisseleva T, Brenner DA.

J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S73-8. Review. Erratum in: J Gastroenterol Hepatol. 2008 Mar;23(3):501-2.

PMID:
17567473
[PubMed - indexed for MEDLINE]
5.

Liver fibrogenesis: a new role for the renin-angiotensin system.

Bataller R, Sancho-Bru P, Ginès P, Brenner DA.

Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1346-55. Review.

PMID:
16115040
[PubMed - indexed for MEDLINE]
6.

[Therapeutical targets for revert liver fibrosis].

García B L, Gálvez G J, Armendáriz B J.

Rev Med Chil. 2007 Jun;135(6):783-91. Epub 2007 Aug 22. Review. Spanish.

PMID:
17728907
[PubMed - indexed for MEDLINE]
Free Article
7.

Liver fibrosis: from the bench to clinical targets.

Pinzani M, Rombouts K.

Dig Liver Dis. 2004 Apr;36(4):231-42. Review. Erratum in: Dig Liver Dis. 2004 Aug;36(8):562-3.

PMID:
15115333
[PubMed - indexed for MEDLINE]
8.

Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension.

Töx U, Steffen HM.

Curr Med Chem. 2006;13(30):3649-61. Review.

PMID:
17168728
[PubMed - indexed for MEDLINE]
9.

Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Gressner AM, Weiskirchen R.

J Cell Mol Med. 2006 Jan-Mar;10(1):76-99. Review.

PMID:
16563223
[PubMed - indexed for MEDLINE]
10.

Fibrosis and cirrhosis reversibility: clinical features and implications.

Pinzani M, Vizzutti F.

Clin Liver Dis. 2008 Nov;12(4):901-13, x. doi: 10.1016/j.cld.2008.07.006. Review.

PMID:
18984473
[PubMed - indexed for MEDLINE]
11.

Hepatic stellate cells and the reversal of fibrosis.

Kisseleva T, Brenner DA.

J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S84-7. Review.

PMID:
16958681
[PubMed - indexed for MEDLINE]
12.

Treatment of hepatic fibrosis: almost there.

Albanis E, Safadi R, Friedman SL.

Curr Gastroenterol Rep. 2003 Feb;5(1):48-56. Review.

PMID:
12530948
[PubMed - indexed for MEDLINE]
13.

Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets?

Schuppan D, Koda M, Bauer M, Hahn EG.

Acta Gastroenterol Belg. 2000 Oct-Dec;63(4):366-70. Review.

PMID:
11233519
[PubMed - indexed for MEDLINE]
14.

Cellular and molecular mechanisms of fibrosis.

Wynn TA.

J Pathol. 2008 Jan;214(2):199-210. Review.

PMID:
18161745
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Renal fibrosis: new insights into the pathogenesis and therapeutics.

Liu Y.

Kidney Int. 2006 Jan;69(2):213-7. Review.

PMID:
16408108
[PubMed - indexed for MEDLINE]
16.

Monocytes and macrophages as cellular targets in liver fibrosis.

Heymann F, Trautwein C, Tacke F.

Inflamm Allergy Drug Targets. 2009 Sep;8(4):307-18. Review.

PMID:
19534673
[PubMed - indexed for MEDLINE]
17.

Hepatic fibrogenesis: the puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules.

Gressner AM.

Z Gastroenterol. 1992 Mar;30 Suppl 1:5-16. Review.

PMID:
1449018
[PubMed - indexed for MEDLINE]
18.

Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review.

Le Bousse-Kerdilès MC, Martyré MC, Samson M.

Eur Cytokine Netw. 2008 Jun;19(2):69-80. doi: 10.1684/ecn.2008.0127. Epub 2008 Jun 1. Review.

PMID:
18632420
[PubMed - indexed for MEDLINE]
19.

Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy.

Inagaki Y, Higashiyama R, Higashi K.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:85-8. doi: 10.1111/j.1440-1746.2011.07006.x. Review.

PMID:
22320923
[PubMed - indexed for MEDLINE]
20.

What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis.

Iwaisako K, Brenner DA, Kisseleva T.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:65-8. doi: 10.1111/j.1440-1746.2011.07002.x. Review.

PMID:
22320919
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk